Evidence map›Paper›PMID 41950000›Full record

ArticleBlood2026

Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution uncovered by single-cell multiomic analysis.

Morgan Drucker, Darren Lee, Michael Bowman, Xuan Zhang, Bailee N Kain, Deedra Nicolet, Roopsha Bandopadhyay, Varsha Singh, Zhe Wang, Richard M Stone and 12 more

Abstract read
In one paragraph

Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Prognostic and Therapeutic Implications ofbioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Morgan DruckerDivision of Oncology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0009-0001-1259-3988
Darren LeeUniversity of Cincinnati College of Medicine, Cincinnati, OH.
Michael BowmanDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Xuan ZhangDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0001-7966-8748
Bailee N KainDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0002-8407-9937
Deedra NicoletThe Ohio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0001-7796-0251
Roopsha BandopadhyayDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0009-0002-9982-9654
Varsha SinghDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-2761-7102
Zhe WangDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0002-9129-4125
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-7526-2633
Caner SayginDepartment of Medicine, University of Chicago, Chicago, IL.ORCID 0000-0001-7617-8356
Krzysztof MrózekThe Ohio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0002-1408-5063
Andrew J CarrollDepartment of Genetics, The University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0001-9844-730X
Daniel T StarczynowskiDepartment of Pediatrics, University of Cincinnati, Cincinnati, OH.ORCID 0000-0002-5771-7462
Ross L LevineHuman Oncology and Pathogenesis Program, Molecular Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-7884-1905
John C ByrdHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA.ORCID 0000-0002-8778-1000
Nathan SalomonisDepartment of Pediatrics, University of Cincinnati, Cincinnati, OH.ORCID 0000-0001-9689-2469
Sarah J SkuliUniversity of Cincinnati Cancer Center, Cincinnati, OH.ORCID 0000-0001-7711-0732
H Leighton GrimesDepartment of Pediatrics, University of Cincinnati, Cincinnati, OH.ORCID 0000-0001-8162-6758
Ann-Kathrin EisfeldThe Ohio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0001-6442-1419
Robert L BowmanDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-8294-8748
Linde A MilesDepartment of Pediatrics, University of Cincinnati, Cincinnati, OH.ORCID 0000-0003-3578-2842

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Xenotransplant and Genome Editing CoreU54DK126108 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Daniel Starczynowski, YI ZHENG · 2021 to 2026
$5.0M
Towards an inclusive genomic risk classification for acute myeloid leukemia (AML)R01CA284595 · NCI · OHIO STATE UNIVERSITY · PI Ann-Kathrin Eisfeld, H. LEIGHTON GRIMES · 2023 to 2026
$2.6M
Understanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AMLR01CA262496 · NCI · OHIO STATE UNIVERSITY · PI Ann-Kathrin Eisfeld, Elaine R. Mardis · 2022 to 2026
$2.6M
The role of inflammation in the regulation of immune response in acute myeloid leukemiaR01CA283574 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Iannis Aifantis, Ann-Kathrin Eisfeld · 2023 to 2026
$2.3M
Post-Graduate Hematology/Oncology Translational (PG-HOT) Training ProgramT32CA236764 · NCI · UNIVERSITY OF CINCINNATI · PI QI, XIAOYANG, SCAGLIONI, PIER PAOLO · 2019 to 2023
$2.1M
Penalized mixture cure models for identifying genomic features associated with outcome in acute myeloid leukemiaR01LM013879 · NLM · OHIO STATE UNIVERSITY · PI ARCHER, KELLIE J. · 2022 to 2025
$1.0M
Interrogating oncogene-dependency and mutation order in FLT3 mutant AMLR00CA248460 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BOWMAN, ROBERT LYLE · 2022 to 2024
$743k
Dissecting the role of clonal evolution in NPM1-mutant AMLR00CA252005 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI MILES, LINDE A · 2022 to 2024
$669k
NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA248460NCI NIH HHS R00 CA252005NCI NIH HHS R01 CA262496NCI NIH HHS R01 CA283574NCI NIH HHS R01 CA284595NCI NIH HHS T32 CA236764NIDDK NIH HHS U54 DK126108NLM NIH HHS R01 LM013879
6 · The paper itself

Abstract

abstractAcute myeloid leukemia (AML) is a multiclonal disease, existing as a milieu of clones with unique but related genotypes as initiating clones acquire subsequent mutations. However, bulk sequencing cannot fully capture AML clonal architecture or the clonal evolution that occurs as patients undergo therapy. To interrogate clonal evolution, we performed simultaneous single-cell molecular profiling and immunophenotyping on 43 samples from 32 patients with NPM1 (nucleophosmin 1)-mutated AML at different time points in disease progression. Here, we show that diagnosis and relapse AML samples display similar clonal architecture patterns, but signaling mutations drive increased clonal complexity, specifically at relapse, which correlates with overall survival. We uncovered unique genotype-immunophenotype relationships regardless of disease state, suggesting leukemic lineage trajectories can be hard-wired by the mutations present. Analysis of longitudinal samples from patients on front-line AML therapy identified dynamic clonal and immunophenotypic changes consistent with the genotype-immunophenotype relationships we identified.

Indexed as

Clonal EvolutionLeukemia, Myeloid, AcuteMutationNuclear ProteinsAdultAgedFemaleGenotypeHumansImmunophenotypingMaleMiddle AgedMultiomicsNucleophosminSingle-Cell AnalysisNPM1 protein, humanNuclear ProteinsNucleophosmin

Identifiers

PMID41950000
PMCPMC13386097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.